文献速递造血干细胞移植与细胞治疗贫血与红细胞疾病

异基因造血干细胞移植治疗白细胞黏附缺陷症I型和III型

Allogeneic hematopoietic stem cell transplantation in leukocyte adhesion deficiency type I and III.
PubMed 文献 · Blood Adv · 2021-01-01

该回顾性多中心研究基于欧洲血液与骨髓移植学会注册库,分析了2007至2017年间33个中心84例接受异基因造血干细胞移植的白细胞黏附缺陷症(LAD)I型和III型患者。全队列3年总生存率为83%,LAD-I为84%,LAD-III为75%;3年无事件生存率为56%。II-IV级急性移植物抗宿主病是死亡的重要危险因素。

要点

  • LAD-I和LAD-III患者allo-HSCT后3年总生存率分别为84%和75%。
  • 3年移植失败累积发生率为17%,100天II-IV级aGVHD累积发生率为24%。

核心结论

  • 异基因造血干细胞移植可使LAD-I和LAD-III患者获得较高的3年总生存率,但移植失败和aGVHD仍影响预后。

研究设计与样本

  • 回顾性多中心研究,数据来自欧洲血液与骨髓移植学会注册库,纳入2007至2017年33个中心84例接受allo-HSCT的LAD患者。

主要发现

  • 全队列3年总生存率估计为83%(95%CI 74-92),LAD-I为84%(75-94),LAD-III为75%(50-100)。
  • 3年移植失败累积发生率为17%(95%CI 9%-26%),100天II-IV级aGVHD累积发生率为24%(15%-34%)。
  • 3年无GVHD且无移植失败的无事件生存率全队列为56%(95%CI 46-69),LAD-I为58%(46-72),LAD-III为56%(23-88)。
  • 移植时年龄≥13个月、非同胞供者、供受体任一血清学CMV不匹配与严重aGVHD和较差无事件生存显著相关。

关键数值与推荐

  • 白消安或苏消安为基础的预处理方案、GVHD预防类型及血清疗法对总生存率、无事件生存率或aGVHD无影响。

临床怎么用

  • allo-HSCT是LAD-I和LAD-III的治愈性治疗,移植后需关注aGVHD及移植失败风险。
  • 供者选择时需考虑非同胞供者及CMV血清学不匹配与不良预后的关联。
  • LAD内在炎症成分可能增加移植期间炎症并发症,可考虑抗炎治疗预处理。

局限性

  • 回顾性研究设计,数据来自注册库,可能存在信息偏倚。
  • LAD-III亚组样本量较小,生存估计置信区间较宽。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Type I and III leukocyte adhesion deficiencies (LADs) are primary immunodeficiency disorders resulting in early death due to infections and additional bleeding tendency in LAD-III. The curative treatment of LAD-I and LAD-III is allogeneic hematopoietic stem cell transplantation (allo-HSCT). In this retrospective multicenter study, data were collected using the European Society for Blood and Marrow Transplantation registry; we analyzed data from 84 LAD patients from 33 centers, all receiving an allo-HSCT from 2007 to 2017. The 3-year overall survival estimate (95% confidence interval [CI]) was 83% (74-92) for the entire cohort: 84% (75-94) and 75% (50-100) for LAD-I and LAD-III, respectively. We observed cumulative incidences (95% CI) of graft failure (GF) at 3 years of 17% (9%-26%) and grade II to IV acute graft-versus-host disease (aGVHD) at 100 days of 24% (15%-34%). The estimate (95% CI) at 3 years for GF- and GVHD-II to IV-free survival as event-free survival (EFS) was 56% (46-69) for the entire cohort; 58% (46-72) and 56% (23-88) for LAD-I and LAD-III, respectively. Grade II to IV acute GVHD was a relevant risk factor for death (hazard ratio 3.6; 95% CI 1.4-9.1; P = .006). Patients' age at transplant ≥13 months, transplantation from a nonsibling donor, and any serological cytomegalovirus mismatch in donor-recipient pairs were significantly associated with severe acute GVHD and inferior EFS. The choice of busulfan- or treosulfan-based conditioning, type of GVHD prophylaxis, and serotherapy did not impact overall survival, EFS, or aGVHD. An intrinsic inflammatory component of LAD may contribute to inflammatory complications during allo-HSCT, thus providing the rationale for considering anti-inflammatory therapy pretreatment.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Bakhtiar S, Salzmann-Manrique E, Blok HJ, et al. Allogeneic hematopoietic stem cell transplantation in leukocyte adhesion deficiency type I and III. Blood Adv. 2021. PMID: 33570653. doi:10.1182/bloodadvances.2020002185

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。